- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06067100
U-LABA/ICS Effects on Exercise Performance, Indacaterol
October 4, 2023 updated by: Morten Hostrup, PhD
Physiological Response to U-LABA/ICS With Emphasis on Exercise Performance, Indacaterol
The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Morten Hostrup, PhD
- Phone Number: +4535321595
- Email: mhostrup@nexs.ku.dk
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Recruiting
- August Krogh Building
-
Contact:
- Morten Hostrup, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age 18-39
- Physically active > 5 h weekly
- Maximal oxygen consumption classified as high or very high
Exclusion Criteria:
- Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
- ECG abnormality
- ACQ score > 1.5
- Severe bronchial hyperreactivity as determined by mannitol test
- FEV1/FVC ratio < 0.7 determined with spirometry
- Chronic illness determined to be a potential risk for participant during study
- In chronic treatment with medication that may interfere with study results
- Pregnancy
- Smoker
- Blood donation during the past 3 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Participants are administered placebo
|
Experimental: Indacaterol + mometasonefluroate
|
Participants are administered 125 µg indacaterol + mometasonefluroate
Participants are administered 500 µg indacaterol + mometasonefluroate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Power output during sprint testing
Time Frame: Through study completion, an average of 3 weeks
|
Power output measured in Watts during a sprint on a bike ergometer
|
Through study completion, an average of 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Power output during time trial
Time Frame: Through study completion, an average of 3 weeks
|
Mean power output measured in Watts during a time trial on a bike ergometer
|
Through study completion, an average of 3 weeks
|
Forced Expiratory Volume in 1 second (FEV1)
Time Frame: Through study completion, an average of 3 weeks
|
FEV1 measured by spirometry
|
Through study completion, an average of 3 weeks
|
Quadriceps strength
Time Frame: Through study completion, an average of 3 weeks
|
Maximal torque (Nm) achieved during isometric contraction
|
Through study completion, an average of 3 weeks
|
Respiratory muscle function
Time Frame: Through study completion, an average of 3 weeks
|
Mouth inspiratory and expiratory pressures (MD Diagnostics, RP-check, handheld respiratory pressure meter)
|
Through study completion, an average of 3 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Morten Hostrup, PhD, University of Copenhagen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 5, 2023
Primary Completion (Estimated)
September 15, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
September 20, 2023
First Submitted That Met QC Criteria
September 27, 2023
First Posted (Actual)
October 4, 2023
Study Record Updates
Last Update Posted (Estimated)
October 9, 2023
Last Update Submitted That Met QC Criteria
October 4, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- INDAC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Exercise Performance
-
Nanyang Technological UniversityRecruitingExercise PerformanceSingapore
-
Nanyang Technological UniversityActive, not recruitingPhysiological Outcomes of High-intensity Interval Training With Post-exercise Blood Flow RestrictionExercise PerformanceSingapore
-
University of Novi Sad, Faculty of Sport and Physical...CompletedExercise PerformanceSerbia
-
University of Illinois at Urbana-ChampaignAlliance for Potato Research and EducationCompleted
-
Intermountain Health Care, Inc.CompletedExercise PerformanceUnited States
-
Morten Hostrup, PhDNot yet recruiting
-
Morten Hostrup, PhDRecruiting
-
BioActorCompletedExercise PerformanceNetherlands
-
Nanyang Technological UniversityCompleted
-
Glac Biotech Co., LtdCompletedExercise PerformanceTaiwan
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States